The impact of follicular lymphoma on health-related quality of life

Annals of Oncology

Volumn 19, Issue 3, 2008, Pages 570-576

  Pettengell, R ^a   Donatti, C ^b   Hoskin, P ^c   Poynton, C ^d   Kettle, P J ^e   Hancock, B ^f   Johnson, S ^g   Dyer, M J S ^h   Rule, S ⁱ   Walker, M ^j   Wild, D ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ICON PLC   (United Kingdom)

^c MOUNT VERNON CANCER CENTRE   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e BELFAST CITY HOSPITAL   (United Kingdom)

^f WESTON PARK HOSPITAL   (United Kingdom)

^g TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^h UNIVERSITY OF LEICESTER   (United Kingdom)

ⁱ DERRIFORD HOSPITAL   (United Kingdom)

^j ROCHE PRODUCTS LTD   (United Kingdom)

more..

Author keywords

FACT LYM; Follicular lymphoma; HRQoL; PRO; Relapse; Remission

Indexed keywords

RITUXIMAB;

ADULT; AGED; ANXIETY; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; DEPRESSION; EMOTIONAL STABILITY; FEMALE; FOLLICULAR LYMPHOMA; FUNCTIONAL STATUS; HEALTH STATUS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUALITY OF LIFE; REGRESSION ANALYSIS; SOCIAL STATUS; UNITED KINGDOM;

EID: 40149088446     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm543     Document Type: Article

References (26)

1. A.K. Ganti R.G. Bociek P.J. Bierman Follicular lymphoma: expanding therapeutic options Oncology 19 2005 213 228
2. ISD Online Cancer Incidence, Mortality and Survival Data 2005 http://www.isdscotland.org/
3. Northern Ireland Cancer Registry. Cancer Registrations in Northern Ireland 2002 http://www.qub.ac.uk/research-centres/nicr/Data/OnlineStatistics/Non-HodgkinsLymphoma/ . (21 November 2007, date last accessed)
4. Office for National Statistics. Cancer Statistics Registrations of Cancer Diagnosed in 2002(Series MB1 no. 33). http://www.statistics.gov.uk/ (21 November 2007, date last accessed)
5. Welsh Cancer Intelligence and Surveillance UnitCancer Registrations in Wales 2002 http://www.wales.nhs.uk/ (21 November 2007, date last accessed)
6. D.M. Parkin P. Pisani J. Ferlay Global cancer statistics CA Cancer J Clin 49 1999 33 64
7. B. Wake C. Hyde S. Bryan Rituximab as third-line treatment for refractory or recurrent stage III or IV follicular non-Hodgkin's lymphoma: a systematic review Health Technol Assess 6 2002 1 85
8. National Comprehensive Cancer NetworkNon-Hodgkin's Lymphoma: Treatment Guidelines for Patients. Version I/October 2003 http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2007.asp/ (21 November 2007, date last accessed)
9. K. Webster D. Cella Quality of life in patients with low-grade non-Hodgkin's lymphoma Oncology 12 1998 697 714
10. D. Cella S. Mahon M. Donavan Cancer recurrence as a traumatic event Behav Med 16 1990 15 22
11. P. McLaughlin Progress and promise in the treatment of indolent lymphomas Oncologist 7 2002 217 225
12. K. Basen-Engquist L. Cohen C. Caramack The Webster/Cella article reviewed Oncology 12 2002 714 717
13. L. Wallwork A. Richardson Beyond cancer: changes, problems and needs expressed by adult lymphoma survivors attending an out-patients clinic Eur J Cancer Care 3 1994 122 132
14. S. Eremenco K. Webster L. Kutikova Development and multilingual validation of the FACT-LYM Presented at ISOQOL Annual Conference. 17th October 2004. Qual Life Res 13 9 2004 1495 1603
15. K. Webster D. Cashy D. Cella Measuring quality of life (QOL) in patients with non-hodgkin's lymphoma (NHL): the Functional Assessment of Cancer Therapy-Lymphoma (FACT-LYM) Qual Life Res 14 2005 2103
16. M. Reilly A. Zbrozek E.M. Dukes The validity and reproducibility of a work productivity and activity impairment instrument Pharmacoeconomics 4 1993 353 365
17. R. Snaith A. Zigmond The Hospital Anxiety and Depression Scale: Manual London, UK: 1994 NFER-Nelson
18. A. Zigmond R. Snaith The Hospital Anxiety and Depression Scale Acta Psychiatr Scand 67 1983 361 370
19. E. Maher Anomic aspects of recovery from cancer Soc Sci Med 16 1982 907 912
20. M. Herold S. Sacchi K. Hieke The cost of treating relapsed indolent non-Hodgkin's lymphoma in an international setting; retrospective analysis of resource use Haematologica 87 2002 719 729
21. W. Hiddemann M. Kneba M. Dreyling Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood 106 2005 3725 3732
22. M.H. van Oers R. Klasa R.E. Marcus Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial Blood 108 2006 3295 3301
23. A.K. Gopal T.A. Gooley D.G. Maloney High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis Blood 102 2003 2351 2357
24. R.J. Schilder T.E. Witzig I. Flinn Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin(R)) induces long-term responses in patients with relapsed or refractory follicular lymphoma (FL) 104 2004 ASH Annual Meeting Abstracts (Abstr 2629)
25. H.C. Schouten W. Qian S. Kvaloy High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial J Clin Oncol 21 2003 3918 3927
26. M. Oken R. Creech D. Tormey Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 655